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Relevance of the International
Prognostic Index in the Rituximab Era
TO THE EDITOR: We read with interest this meta-anaylsis by Ziepert
et al1 involving 1,062 patients with diffuse large B-cell lymphoma accrued
fromthreeprospectivephaseII/IIItrials:MinT(Mab-TheraInternational
Trial), RICOVER-60 (cyclophosphamide, doxorubicin, vincristine, and
prednisone plus rituximab [R-CHOP] for patients older than age 60
years), and MegaCHOEP (dose-escalated regimen of cyclophosphamide,
doxorubicin,vincristine,etoposide,andprednisone)trials.2-4 Theauthors
affirms the prognostic relevance of the International Prognostic Index
(IPI) score for all three end points of progression-free survival, event-free
survival,andoverallsurvival.Thus,theyconcludedthatIPIshouldremain
the major tool for risk stratification for patients with diffuse large B-cell
lymphoma in the era of rituximab.
While we agree with Ziepert et al1 that the IPI will remain an impor-
tant prognostic tool until a new scoring system or novel prognostic mark-
ers are validated, we would like to address several issues raised in this
article. Firstly, it should be noted that different chemotherapy regimens
wereusedinthethreetrialsfromwhichdatawascollected.Patientstreated
with MegaCHOEP were given high-dose chemotherapy that was used as
a mobilization regimen for autologous stem-cell transplantation.4 Like-
wise, it is unclear if the efficacy of R-CHOP14 which was studied in the
RICOVER-60 trial, is similar to R-CHOP21 which was used in approxi-
mately 50% of patients in the MinT trial.2,3 Ziepert et al must have be-
lieved that these regimens are of different efficacies and thus applied them
todifferentprognosticgroupsasdefinedbytheIPI.5Prognosticfactorsare
dependent on the efficacy of the regimen used.6,7 However, in this analy-
sis, the patients were combined and analyzed together as though there are
nodifferencesintheefficaciesoftheregimensusedandpriorstratification
unimportant. It would be helpful for Ziepert et al to clarify the statistical
validity of combining patients with different prognostic risks treated with
separate regimens with potentially varying efficacy in the same analysis.
Ziepert et al1 also highlighted that their data set contained an over-
representation of patients with good risk factors. Conversely, we would
like to point out that there is an under-representation of young high-risk
patients in their data set. Only 55 young patients with two or more risk
factors, out of a total number of 1,062 patients were included in the
analysis. In fact, almost 60% of the patients in the analysis were obtained
from the RICOVER-60 trial. Thus, the findings of this analysis could
potentially be a reflection of the RICOVER-60 trial.
Furthermore, it is conceivable that with the introduction of ritux-
imab, previously identified prognostic factors may no longer be relevant.
Thus, simply adopting an index that comprises of prognostic factors
derived from the prerituximab era may be less applicable. Using the IPI in
this analysis, the authors will not be able to identify any subgroup with an
overall survival less than 59%. In addition, the multivariate analysis re-
ported in this study, only demonstrated four out of the five IPI factors
retained their prognostic relevance. It might be more useful to use these
factors identified in the rituximab era to construct a new prognos-
tic model.
We also retrospectively compared the prognostic factors of 320 pa-
tients treated with R-CHOP at our institution from 2000 to 2008. While
factors such as performance status, stage, lactate dehydrogenase level, age,
B symptoms, bone marrow involvement, and more than one extra-nodal
site of involvement were significant prognostic factors on univariate anal-
ysis,onlyperformancestatusandbonemarrowinvolvementremainedas
independent prognostic factors on multivariate analysis. In our analysis,
althoughIPIwasstillpredictiveof survival, it couldonly identify threerisk
groupsofpatientsandcouldnolongeridentifypatientswithlessthan60%
chance of survival, consistent with the findings of Ziepert et al1 as well as
with an earlier report by Sehn et al.8
Therefore, rather than relying on the IPI alone, it would be useful
to identify new clinical and molecular factors that can better identify
patients at high risk of treatment failure in the rituximab era. The
relevance of previously identified risk factors should also be individu-
ally reconfirmed in the rituximab era so that the prognostic index is
more robust and relevant.
Kevin Tay, David Tai, Miriam Tao, Richard Quek,
Tam-Cam Ha, and Soon-Thye Lim
National Cancer Center Singapore, Singapore
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The author(s) indicated no potential conflicts of interest.
REFERENCES
1. Ziepert M, Hasenclever D, Kuhnt E, et al: Standard International Prognostic
Index remains a valid predictor of outcome for patients with aggressive CD20
B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373-2380, 2010
2. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy
plus rituximab versus CHOP-like chemotherapy alone in young patients with
good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by
the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
3. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of
bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive
CD20 B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet
Oncol 9:105-116, 2008
4. Glass B, Kloess M, Bentz M, et al: Dose-escalated CHOP plus etoposide (Mega-
CHOEP) followed by repeated stem cell transplantation for primary treatment of
aggressive high-risk non-Hodgkin lymphoma. Blood 107:3058-3064, 2006
5. Anonymous: A predictive model for aggressive non-Hodgkin’s lymphoma.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl
J Med 329:987-994, 1993
6. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly
CHOP chemotherapy with or without etoposide for the treatment of elderly
patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL.
Blood 104:634-641, 2004
7. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly
CHOP chemotherapy with or without etoposide for the treatment of young
patients with good-prognosis (normal LDH) aggressive lymphomas: Results of
the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004
8. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index
(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large
B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007
DOI: 10.1200/JCO.2010.31.7677; published online ahead of print at
www.jco.org on November 29, 2010
■ ■ ■
JOURNAL OF CLINICAL ONCOLOGY C O R R E S P O N D E N C E
VOLUME 29  NUMBER 1  JANUARY 1 2011
e14 © 2010 by American Society of Clinical Oncology Journal of Clinical Oncology, Vol 29, No 1 (January 1), 2011: p e14
Downloaded from ascopubs.org by 203.10.91.85 on May 17, 2018 from 203.010.091.085
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
